Vendor Intelligence Report: Lipeptides
Published 12 Nov 2026. 31-page investigative report on who is behind Lipeptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.
Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.
Executive summary
Across 85 Finnrick lab tests, Lipeptides records 63 pass / 21 fail, for a 74% overall pass rate. The headline is useful only if read product by product. Retatrutide is the clearest strength and the deepest line in the record, with GHK-Cu and Tirzepatide also comparatively defensible with lot discipline; NAD+, KPV, TB-500 and BPC-157 are weak enough that buyers should not extrapolate from Retatrutide. The full report also shows where ratings move under stricter purity and fill thresholds.
The non-lab investigation is where the vendor becomes more complicated. Public records identify a young Shoplazza retail surface, not a registry-verified legal owner, and the About page repeats Body Good Studio-origin language with a misnamed founder while making unsupported in-house lab claims. That is a transparency finding, not proof that qualified people do not exist; the buyer-relevant issue is that sourcing, QA and release authority cannot be verified from public materials.
Certificate and infrastructure evidence links lipeptide.com to a Lili-branded cluster: matching Janoshik result values appear under different client and manufacturer fields, and sister stores share agents, registrar/DNS patterns and product mappings. At the same time, the public COA set is July 2025, Batch Unknown, and not tied to current vial-level verification. The catalogue also reaches beyond ordinary research peptides into botulinum toxin, EPO and hCG, while retail reviews combine real-delivery reports with recurring post-payment fee allegations.
Inside the full report:
- Complete per-product pass/fail rates and methodology-divergence charts for all 9 tested products
- Side-by-side Janoshik COA inventory comparing Lipeptides and Lili certificate fields
- RDAP, DNS and storefront map for linked sister stores, suspended lookalikes and unattributed same-name channels
- Contact-roster, Telegram, TikTok/Skool, directory and escrow-channel analysis
- Trustpilot review-cluster analysis and post-payment fee allegation timeline
- Catalogue, COA, payment-rail and buyer-recourse assessment, including botulinum toxin, EPO and hCG listings
Risk assessment
- Product-specific laboratory quality risk — high: Lipeptides tests well on Retatrutide, GHK-Cu and Tirzepatide, but BPC-157 48.01%, NAD+ 22.83%, TB-500 36.32%, KPV 22.05% and Tesamorelin 48.5% are materially weak.
- Ownership and corporate-identity risk — high: No public UBO or registry-verified legal entity was found; Lipeptide/Lilitide/Lilitai names are inconsistent and the About page uses copied Body Good language.
- Current-lot verification and COA traceability risk — high: Lipeptides COAs are July 2025 and Batch Unknown; no lot lookup or anti-counterfeit list is published, and sister certificates share identical values under different client names.
- Post-payment fee escalation and buyer-recourse risk — high: Trustpilot and Reddit allegations describe added insurance, customs, testing or permit fees after payment, including a bitcoin demand; WU/T/T/BTC payment rails reduce recourse.
- High-hazard catalogue-scope risk — high: Botulinum toxin, EPO and hCG are listed with generic 99% / foil-bag claims and no Finnrick testing or public control evidence.
- Brand/channel-confusion risk — medium: Linked Lili stores, suspended near-name domains and unrelated same-name stores create confusion; the vendor lacks an official-channel or authorized-reseller list.
- Review-reliability risk — medium: The Trustpilot profile is small and polarized, with six five-star reviews in 72 hours, five from single-review accounts, and continuing one-star fee allegations.